<DOC>
	<DOCNO>NCT00289172</DOCNO>
	<brief_summary>Rotavirus disease common cause gastroenteritis dehydration young child worldwide . The global public health burden prompt development human rotavirus vaccine rotavirus disease GlaxoSmithKline Biologicals . This pre-registration study undertaken provide immunogenicity , reactogenicity safety data vaccine use Indian infant age approximately 8 week time first dose .</brief_summary>
	<brief_title>Assess Immunogenicity &amp; Safety 2 Doses Oral Live Attenuated Human Rota ( HRV ) Vaccine Healthy Infants India</brief_title>
	<detailed_description>The study consist two group child recruit different center India . One group receive HRV vaccine one group receive placebo . The vaccine placebo administer start 8-12 week age , accord two dose schedule ( 0 , 1 month schedule ) . The study consist three visit . A 8-day ( Day 0 - 7 ) follow-up period observe general symptom solicit study . A 31-day ( Day 0 - 30 ) follow-up observe unsolicited symptom . Serious adverse event ( SAEs ) followed-up throughout study . A stool sample collect child point study he/ develops GE .</detailed_description>
	<mesh_term>Gastroenteritis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>`` Inclusion criterion : A male female , include , 8 10 week age time first vaccination . Written inform consent obtain parent guardian subject . Free obvious health problem establish medical history clinical examination enter study . The subject administer first dose DTP/ OPV/ hepatitis B vaccine per local universal immunization program 6 week age . Exclusion criterion : Use investigational nonregistered product ( drug vaccine ) study vaccine routine UIP vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug since birth . ( For corticosteroid , mean prednisone , equivalent , &gt; = 0.5 mg/kg/day . Inhaled topical steroid allow . ) Any chronic drug therapy continue study period . Administration vaccine foreseen study protocol within 6 week first dose vaccine plan administration study vaccine foreseen study protocol , exception diphtheria , tetanus , pertussis , hepatitis B , Haemophilus influenzae type b ( Hib ) , OPV vaccination tuberculosis , give least two week separation first subsequent dose study vaccine . Prior administration experimental rotavirus vaccine . History confirm rotavirus gastroenteritis . Any clinically significant history chronic gastrointestinal disease include uncorrected congenital malformation GI tract serious medical condition determine investigator . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection base physical examination ( laboratory testing require ) . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine . Major congenital defect serious chronic illness . History neurologic disorder seizure . Acute disease time enrolment . Gastroenteritis ( diarrhea ) within 7 day precede study vaccine administration ( warrant deferral vaccination ) . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination medical history . Administration immunoglobulins and/or blood product since birth plan administration study period . Oral intake immunoglobulin via breastfeeding allow .</criteria>
	<gender>All</gender>
	<minimum_age>8 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>